Manufacturing Troubleshooting for Pharmaceutical Solid Forms

Problems Triclinic can help with

Each molecule has a unique physical-property profile. A single screening protocol or standard analytical package does not fit every solid-form problem. Triclinic helps interpret existing data, design targeted experiments, and identify the shortest path to the cause.

Problem areas include non-optimal drug-substance properties, late-stage form changes, salt selection, cocrystal development, amorphous stability, analytical method development, ultra-low-loading release testing, contaminant identification, counterfeit analysis, prior-art reproduction, chiral resolution, and cGMP or non-GMP crystallization method development.

• Solubility, stability, crystallization failure, hygroscopicity, manufacturability, filterability, and compressibility issues
• Polymorphic determination and control, including late-stage form changes
• Analytical method development, validation, and release testing at very low loading
• Failure on storage or stability, drug-product appearance changes, or batch-dependent performance
• Interpretation of prior experiments and design of focused follow-up studies

A useful troubleshooting plan distinguishes between material change and method limitation. A new result may reflect a real form conversion or contamination event, but it may also reflect preferred orientation, low-level detection limits, excipient interference, sample handling, or a non-specific method.

Method choice must match the failure mode

For drug products, method specificity should be treated as part of the root-cause question. A method that identifies neat API may not identify the same low-level phase in an excipient matrix without validation or orthogonal confirmation.

How Triclinic scopes a solid-form troubleshooting investigation

A troubleshooting project should not start with a broad analytical shopping list. It should start with the symptom, the decision deadline, the batch history, and the shortest credible set of hypotheses that can explain the failure.

Triclinic looks for evidence that connects the observed failure to a material change, analytical method limitation, contamination or mix-up, process variable, humidity or solvent exposure, particle attribute, or solid-form conversion. The goal is not more data; it is a defensible root-cause path and a control recommendation.

1. Frame the failure mode. Define the observed change: OOS result, dissolution drift, stability failure, new XRPD peak, DSC change, lot-to-lot PK scatter, water uptake, visual change, or process inconsistency.
2. Reconstruct material history. Compare retained lots, supplier batches, processing steps, humidity and solvent exposure, milling, granulation, drying, packaging, and analytical methods.
3. Test competing hypotheses. Use targeted XRPD, Raman/IR, DSC/TGA, DVS, Karl Fischer, chromatography, microscopy, LC/MS, GC/MS, chemometrics, or stress studies only where they answer the failure hypothesis.
4. Report the control path. Separate proven cause, likely cause, ruled-out causes, analytical limitations, and recommended next controls or confirmatory experiments.

Do not call it formulation noise until solid form is checked

PK scatter, dissolution drift, stability failure, process sensitivity, or lot-to-lot differences should be tested against polymorph, hydrate, solvate, salt, cocrystal, particle habit, and amorphous-content hypotheses before they are written off as ordinary formulation variability.

The material state can change across crude API, recrystallized API, wet cake, dried cake, micronized powder, wet-granulated intermediates, dried granules, tablets, dissolution residues, and stability samples. Troubleshooting should map those material states rather than inspect only one retained powder.